Adamas Announces New Employment Inducement Grant
08 févr. 2019 18h49 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three...
Adamas Announces New Employment Inducement Grant
10 janv. 2019 16h30 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 10, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new...
Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019
06 janv. 2019 11h38 HE
|
Adamas Pharmaceuticals, Inc.
-- GOCOVRI preliminary net sales of approximately $13.3 million for the fourth quarter of 2018 and approximately $34 million for the year -- -- Preliminary total prescriptions of approximately 5,700...
Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI™
18 déc. 2018 16h30 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas to Present at Three November Investor Conferences
09 nov. 2018 13h49 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Reports Third Quarter 2018 Financial Results
01 nov. 2018 16h01 HE
|
Adamas Pharmaceuticals, Inc.
GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) --...
Adamas to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 1, 2018
26 oct. 2018 09h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas Presents Final Results from the Two-Year, Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
08 oct. 2018 08h30 HE
|
Adamas Pharmaceuticals, Inc.
GOCOVRI was generally well tolerated and the safety profile was consistent with previously reported data for up to two yearsResults show a comparable 35% reduction from baseline in dyskinesia and OFF...
Adamas Announces New Employment Inducement Grant
05 oct. 2018 17h51 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted nine new...
Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease
04 oct. 2018 09h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...